

Financial Tear Sheet

Corporate Profile

We are a clinical stage biopharmaceutical company developing novel therapies for the management of pain and other central nervous system, or CNS, disorders. By focusing on this therapeutic area, we are addressing significant and growing markets where current treatment options are limited or inadequate. Our product candidate portfolio includes two late-stage candidates, AXS-02 and AXS-05, which we are developing for multiple indications.

We aim to become a fully integrated biopharmaceutical company that develops and commercializes differentiated therapies that expand the treatment options available to caregivers and improve the lives of patients living with pain and other CNS disorders.

Stock Information

AXSM (Common Stock)

Exchange	NASDAQ (US Dollar)
Price	\$2.65
Change (%)	▼ 0.05 (1.85%)
Volume	89,510
52 Week High	\$6.45
52 Week Low	\$2.45
Market Cap	\$68,831,078
Rolling EPS	-1.29
PE Ratio	0
Shares Outstanding	25,492,992



Data as of March 22, 2018 4:00 p.m. ET

Recent Headlines

March 19, 2018
Axsome Therapeutics to Present at 17th Annual
Needham Healthcare Conference

March 12, 2018
Axsome Therapeutics Presents Scientific
Rationale for the Development of AXS-05 at the
20th Annual Meeting of the American Society for
Experimental Neurotherapeutics

March 7, 2018
Axsome Therapeutics Reports Fourth Quarter and
Full Year 2017 Financial Results and Provides
Business Update

SEC Filings

Filing Date	Form
March 7, 2018	10-K
March 7, 2018	8-K
February 26, 2018	8-K
February 14, 2018	SC 13G/A

Upcoming Events

Date	Title
March 28, 2018 10:00 a.m. ET	<u>Axsome Therapeutics, Inc. at Needham Healthcare Conference (phoenix.zhtml?c=254022& p=&EventId=5269644)</u> Location: The Westin New York Grand Central Hotel New York, NY
